Patents by Inventor Michele L. R. Heffernan

Michele L. R. Heffernan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and compositions and uses thereof
    Patent number: 11958862
    Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: April 16, 2024
    Assignees: Sumitomo Pharma America, Inc., PGI Drug Discovery LLC
    Inventors: Linghong Xie, Michele L. R. Heffernan, Philip Glyn Jones, Taleen G. Hanania
  • Heteroaryl-isochroman compounds and uses thereof
    Patent number: 11491133
    Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: November 8, 2022
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Carrie A. Bowen, Douglas F. Burdi, Michele L. R. Heffernan, Lee W. Herman, Linghong Xie
  • COMPOUNDS AND COMPOSITIONS AND USES THEREOF
    Publication number: 20220340588
    Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
    Type: Application
    Filed: January 11, 2021
    Publication date: October 27, 2022
    Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Linghong XIE, Michele L.R. HEFFERNAN, Philip Glyn JONES, Taleen G. HANANIA
  • Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
    Patent number: 11186564
    Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: November 30, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Scott P. Brown, Lee W. Herman
  • COMPOUNDS AND USES THEREOF
    Publication number: 20210093606
    Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.
    Type: Application
    Filed: August 12, 2020
    Publication date: April 1, 2021
    Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Carrie A. Bowen, Douglas F. Burdi, Michele L. R. Heffernan, Lee W. Herman, Linghong Xie
  • Compounds and compositions and uses thereof
    Patent number: 10927124
    Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: February 23, 2021
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Linghong Xie, Michele L. R. Heffernan, Philip Glyn Jones, Taleen G. Hanania
  • Compounds and uses thereof
    Patent number: 10780074
    Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: September 22, 2020
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Carrie A. Bowen, Douglas F. Burdi, Michele L. R. Heffernan, Lee W. Herman, Linghong Xie
  • Metabotrophic glutamate receptor 5 modulators and methods use thereof
    Patent number: 10640510
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 5, 2020
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF
    Publication number: 20200079778
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: December 6, 2018
    Publication date: March 12, 2020
    Inventors: Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Metabotrophic glutamate receptor 5 modulators and methods of use thereof
    Patent number: 10533000
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: January 14, 2020
    Assignee: Sunovion Pharmaceuticals, Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat
  • COMPOUNDS AND COMPOSITIONS AND USES THEREOF
    Publication number: 20190308990
    Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
    Type: Application
    Filed: December 10, 2018
    Publication date: October 10, 2019
    Applicants: PGI Drug Discovery LLC
    Inventors: Linghong Xie, Michele L.R. Heffernan, Philip Glyn Jones, Taleen G. Hanania
  • DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS
    Publication number: 20190194163
    Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
    Type: Application
    Filed: August 4, 2016
    Publication date: June 27, 2019
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L.R. HEFFERNAN, Larry Wendell HARDY, Scott P. BROWN, Lee W. HERMAN
  • METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF
    Publication number: 20190135815
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: December 6, 2018
    Publication date: May 9, 2019
    Inventors: Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF
    Publication number: 20190055204
    Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Inventors: Larry Wendell Hardy, Michele L.R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • COMPOUNDS AND USES THEREOF
    Publication number: 20190038594
    Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.
    Type: Application
    Filed: August 1, 2018
    Publication date: February 7, 2019
    Inventors: Carrie A. Bowen, Douglas F. Burdi, Michele L.R. Heffernan, Lee W. Herman, Linghong Xie
  • Metabotrophic glutamate receptor 5 modulators and methods use thereof
    Patent number: 10196399
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: February 5, 2019
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Compounds and compositions and uses thereof
    Patent number: 10196403
    Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: February 5, 2019
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Taleen G. Hanania, Michele L. R. Heffernan, Philip Glyn Jones, Linghong Xie
  • Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
    Patent number: 10077243
    Abstract: Provided herein are compounds of formula (I): and pharmaceutical compositions thereof, useful for the treatment of disorders mediated by metabotropic glutamate receptor 5.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: September 18, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF
    Publication number: 20180037585
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: June 16, 2017
    Publication date: February 8, 2018
    Inventors: Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • COMPOUNDS AND COMPOSITIONS AND USES THEREOF
    Publication number: 20180030064
    Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
    Type: Application
    Filed: July 28, 2017
    Publication date: February 1, 2018
    Inventors: Linghong XIE, Michele L.R. HEFFERNAN, Philip Glyn JONES, Taleen G. HANANIA